DiaMedica Therapeutics Inc. (DMAC) Financials

DMAC Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 53.1 million 5.8 million
Dec. 31, 2025 61.4 million 5.3 million
Sept. 30, 2025 57.0 million 5.4 million
June 30, 2025 31.5 million 4.3 million

DMAC Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -9.1 million 822000
Dec. 31, 2025 -7.8 million 1.2 million
Sept. 30, 2025 -6.6 million 1.0 million
June 30, 2025 -7.6 million 771000

DMAC Net Income

No data available :(

DMAC Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 51.3 million 97000 -
Dec. 31, 2025 59.9 million - 128000
Sept. 30, 2025 55.3 million - 157000
June 30, 2025 30.0 million - 292000

DMAC Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 53.8 million
Dec. 31, 2025 47.0 million
Sept. 30, 2025 49.6 million
June 30, 2025 43.0 million

DMAC Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 8000 8.0 million 2.5 million -
Dec. 31, 2025 6000 6.7 million 2.5 million -
Sept. 30, 2025 16189 6.4 million 2.6 million -
June 30, 2025 6000 5.8 million 2.2 million -

DMAC Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 11000
Dec. 31, 2025 -27999 13999
Sept. 30, 2025 - 18000
June 30, 2025 - 3000

DMAC

Price: $5.69

52 week price:
3.48
10.42

Earnings Per Share: -0.71 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 67400

Market Capitalization: 303.9 million

Links: